15 Crosby Drive
Bedford, MA 01730
United States
781 357 4000
https://www.ocutx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 267
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Donald Notman Jr. | Chief Financial Officer | 630.87k | N/D | N/D |
Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer | 84.88k | N/D | 1961 |
Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer | 621.39k | N/D | 1969 |
Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO | N/D | N/D | 1964 |
Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Chief Operations Officer | N/D | N/D | N/D |
Dr. Peter K. Jarrett Ph.D. | Chief Technology Officer | N/D | N/D | 1957 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
La calificación ISS Governance QuickScore de Ocular Therapeutix, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 8; Junta: 6; Derechos del accionista: 7; Compensación: 10.